Search Videos by Topic or Participant
Browse by Series:

Emerging Therapies in Non-Small Cell Lung Cancer

Discussant: H. Jack West, MD
Published: Friday, Dec 05, 2014
For High-Definition, Click
H. Jack West, MD, discusses the growing number of targeted therapies becoming available as treatments for patients with non-small cell lung cancer (NSCLC). This field began with EGFR and ALK inhibitors and was quickly expanded to ROS1. Additionally, the targets for therapies are still expanding further into HER2, BRAF, MET, and others.
 
Each of these targeted agents is for small patient populations of 1% to 3%; however, as more agents are found, this benefit begins to add up toward a large section of the total population. Future advances in this field are eagerly anticipated. 
Slider Left
Slider Right
For High-Definition, Click
H. Jack West, MD, discusses the growing number of targeted therapies becoming available as treatments for patients with non-small cell lung cancer (NSCLC). This field began with EGFR and ALK inhibitors and was quickly expanded to ROS1. Additionally, the targets for therapies are still expanding further into HER2, BRAF, MET, and others.
 
Each of these targeted agents is for small patient populations of 1% to 3%; however, as more agents are found, this benefit begins to add up toward a large section of the total population. Future advances in this field are eagerly anticipated. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x